Total
0
Shares
Orthocell (ASX:OCC) - CEO Paul Anderson with intern Margeux Steltz - The Market Herald
CEO Paul Anderson with intern Margeux Steltz
Source: Orthocell
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Regenerative medicine company Orthocell (OCC) secures Chinese and New Zealand patents for its novel CelGro collagen medical device 
  • The patents, titled “Sutureless repair of soft tissue”, are now approved in Australia, New Zealand, China and Japan, with further applications progressing in US and Europe
  • The patents are set to expire on 12 October 2035
  • Orthocell was up 1.77 per cent, trading at 57.5 cents per share at 11:45 am AEST

Regenerative medicine company Orthocell (OCC) has secured Chinese and New Zealand patents for its novel CelGro collagen medical device for soft tissue regeneration.

The patents, titled “Sutureless repair of soft tissue,” are now approved in Australia, New Zealand, China and Japan, with further applications progressing in US and Europe.

Sutureless repair of soft tissue means repairing damaged soft tissue without the use of damaging stitches.

Orthocell said sutureless repair had the potential to greatly improve the efficiency of surgical procedures by simplifying techniques, reducing surgery time and reducing the risk of additional trauma to soft tissue caused by the use of stitches.

Orthocell’s patented method of sutureless repair involves the use of CelGro, the company’s resorbable collagen medical device. CelGro acts as a cell scaffold when implanted at the site of tissue injury, encouraging new cell growth. Cells from the regenerating tissue integrate with the collagen fibres to guide tissue regeneration.

“These patents are an important addition to our global intellectual property portfolio, further strengthening our position in regenerative medicine product development and novel surgical techniques for soft tissue repair,” Orthocell Managing Director Paul Anderson said.

“This comes at a perfect time for the company as we move our exciting pipeline products in nerve, tendon and ligament repair through the registration process in the US, European Union and Australia."

The patents are set to expire on 12 October 2035.

Orthocell was up 1.77 per cent, trading at 57.5 cents per share at 11:45 am AEST.


OCC by the numbers
More From The Market Herald
BARD1 Life Sciences (ASX:BD1) - CEO, Leearne Hinch - The Market Herald

" BARD1 Life Sciences (ASX:BD1) updates the market on Q4

BARD1 Life Sciences (BD1) has reported advances across its sales, business development and commercialisation activities over the June quarter.
Incannex Healthcare (ASX:IHL) - Chief Medical Officer, Dr Sud Agarwal (centre) - The Market Herald

" Incannex Healthcare (ASX:IHL) has a progressive fourth quarter

Incannex Healthcare (IHL) has spent the fourth quarter progressing its cannabinoid pharmaceutical products and psychedelic medicine therapies.
Prescient Therapeutics (PTX) - CEO & Managing Director, Steven Yatomi Clarke - The Market Herald

" Prescient Therapeutics (ASX:PTX) advances clinical studies in June quarter

Prescient Therapeutics (PTX) has summarised its operations and cashflow for the June quarter.
Mesoblast (ASX:MSB) - Managing Director & CEO, Silviu Itescu - The Market Herald

" Mesoblast (ASX:MSB) trades lower following June quarterly report

Drug developer Mesoblast (MSB) is trading red following the release of its latest quarterly financial report.